FGF19 encodes the ligand for FGFR4, and it was previously shown that FGF19 amplifications corresponded with constitutive activation of FGF receptor 4 (FGFR4)-dependent ERK/AKT-p70S6K-S6 signaling activation in head and neck squamous carcinoma cells37; thus, raising the question as to whether the FGF19/FGFR4 axis also acts as an oncogenic driver in these NSCLC patients and represents a therapeutic target. This evidence concerns the gene FGFR4 and non-small cell lung carcinoma.